- PMID:
29266803
- Authors:
- Johannes J, Denz CR, Su N, Wu A, Impastato AC, Mlynarski S, Varnes JG, Prince DB, Cidado J, Gao N, Haddrick M, Jones NH, Li S, Li X, Liu Y, Nguyen TB, O'Connell N, Rivers E, Robbins DW, Tomlinson R, Yao T, Ferguson AD, Lamb ML, Manchester JI, Guichard S
- Title:
- Structure Based Design of Selective Non-covalent CDK12 Inhibitors.
- Journal:
- ChemMedChem. 2017 Dec 20. doi: 10.1002/cmdc.201700695.
- Abstract:
- CDK12 knockdown via siRNA reduces transcription of DNA damage response genes and sensitizes BRCA wild type cells to PARP inhibition. To recapitulate this effect with a small molecule, we sought a potent, selective CDK12 inhibitor. Crystal structures and modeling informed hybridization between dinaciclib and SR-3029, resulting in lead compound 5. Further structure guided optimization delivered a series of selective CDK12 inhibitors, including compound 7. Profiling of this compound across CDK9, 7, 2 and 1 at high ATP concentration, single point kinase panel screening against 352 targets at 0.1 microM, and proteomics via kinase affinity matrix technology demonstrated selectivity. This series of compounds inhibit phosphorylation of Ser2 on the C-terminal repeat domain of RNA pol II, consistent with CDK12 inhibition. These selective compounds were also acutely toxic to OV90 as well as THP1 cells.